Neurosarcoidosis: Presentations and management

Neurologist

Volumn 16, Issue 1, 2010, Pages 2-15

  Terushkin, Vitaly ^a   Stern, Barney J ^b   Judson, Marc A ^c   Hagiwara, Mari ^a   Pramanik, Bidyut ^a   Sanchez, Miguel ^a   Prystowsky, Stephen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Neurosarcoidosis; Review; Sarcoidosis; Sarcoidosis imaging

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLOROQUINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; FOLIC ACID; GADOLINIUM; GALLIUM 67; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THALIDOMIDE; VITAMIN D;

ADRENAL SUPPRESSION; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; BONE MARROW SUPPRESSION; BRAIN DAMAGE; CARDIOTOXICITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CRANIAL NEUROPATHY; DELAYED HYPERSENSITIVITY; DEMYELINATION; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAM; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEARING IMPAIRMENT; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INFERTILITY; INFLAMMATION; INSOMNIA; INTERSTITIAL PNEUMONIA; LEUKEMIA; LEUKOPENIA; LICHEN PLANUS; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MACROCYTIC ANEMIA; MALARIA; MENINX DISORDER; MYOPATHY; NEUROPHYSIOLOGY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PANCYTOPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RECOMMENDED DRUG DOSE; RETINA INJURY; REVIEW; SARCOIDOSIS; SEIZURE; SIDE EFFECT; SPINAL CORD DISEASE; TINNITUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UREMIA; WEIGHT GAIN;

BRAIN; BRAIN DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; SARCOIDOSIS; SPINAL CORD DISEASES;

EID: 75749137408     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181c92a72     Document Type: Review

References (133)

1. James DG, Sharma OP. Neurosarcoidosis. Proc R Soc Med. 1967;60:1169-1170.
2. Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. Acta Pathol Jpn. 1993;43:372-376.
3. Hunninghake GW, Costabel U, Ando M, et al; American Thoracic Society/ European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-173. (Pubitemid 29469097)
4. Hoitsma E, Faber CG, Drent M, et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3:397-407.
5. Hosoda Y, Sasagawa S, Yasuda N. Epidemiology of sarcoidosis: new frontiers to explore. Curr Opin Pulm Med. 2002;8:424-428.
6. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.
7. Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001;248:363-372.
8. Ricker W, Clark M. Sarcoidosis: a clinical pathological review of 300 cases. Am J Clin Pathol. 1949;19:725-749.
9. Judson MA. Cardiac sarcoidosis: there is no instant replay. Chest. 2005; 128:3-6.
10. Judson MA. Hepatic, splenic, and gastrointestinal involvement with sarcoidosis. Semin Respir Crit Care Med. 2002;23:529-541.
11. Westney GE, Judson MA. Racial and ethnic disparities in sarcoidosis: from genetics to socioeconomics. Clin Chest Med. 2006;27:453- 462, vi.
12. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21.
13. Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52:875-879.
14. Zissel G, Prasse A, Muller-Quernheim J. Sarcoidosis-immunopathogenetic concepts. Semin Respir Crit Care Med. 2007;28:3-14.
15. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324-1330.
16. Kucera GP, Rybicki BA, Kirkey KL, et al. Occupational risk factors for sarcoidosis in African-American siblings. Chest. 2003;123:1527-1535.
17. Gorham ED, Garland CF, Garland FC, et al. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975-2001. Chest. 2004;126:1431-1438.
18. Prezant DJ, Dhala A, Goldstein A, et al. The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest. 1999;116:1183-1193.
19. Izbicki G, Chavko R, Banauch GI, et al. World Trade Center "sarcoid-like" granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007;131:1414-1423.
20. Kajdasz DK, Lackland DT, Mohr LC, et al. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol. 2001;11:111-117.
21. Rybicki BA, Amend KL, Maliarik MJ, et al. Photocopier exposure and risk of sarcoidosis in African-American sibs. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:49-55.
22. Brewerton DA, Cockburn C, James DC, et al. HLA antigens in sarcoidosis. Clin Exp Immunol. 1977;27:227-229.
23. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73:720-735.
24. Iannuzzi MC, Maliarik MJ, Poisson LM, et al. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med. 2003;167:1225-1231.
25. Rybicki BA, Walewski JL, Maliarik MJ, et al. The BTNL2 gene and sarcoidosis susceptibility in African Americans and whites. Am J Hum Genet. 2005;77:491-499.
26. Smith G, Brownell I, Sanchez M, et al. Advances in the genetics of sarcoidosis. Clin Genet. 2008;73:401-412.
27. Hoitsma E, Sharma OP. Neurosarcoidosis. Eur Respir Mon. 2005;32:164-187.
28. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis- diagnosis and management. QJM. 1999;92:103-117.
29. Plotkin GR, Patel BR. Neurosarcoidosis presenting as chronic lymphocytic meningitis. Pa Med. 1986;89:36-37.
30. Mayer SA, Yim GK, Onesti ST, et al. Biopsy-proven isolated sarcoid meningitis. Case report. J Neurosurg. 1993;78:994-996.
31. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42:909-917.
32. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med. 1977;87:336-345. (Pubitemid 8177365)
33. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7:234-244.
34. Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol. 1991;48:842-844.
35. Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med. 2008;29:475-492.
36. Veres L, Utz JP, Houser OW. Sarcoidosis presenting as a central nervous system mass lesion. Chest. 1997;111:518-521.
37. Powers WJ, Miller EM. Sarcoidosis mimicking glioma: case report and review of intracranial sarcoid mass lesions. Neurology. 1981;31:907-910.
38. Urich H. Neurosarcoidosis or granulomatous angiitis: a problem of definition. Mt Sinai J Med. 1977;44:718-725.
39. Colover J. Sarcoidosis with involvement of the nervous system. Brain. 1948;71(pt 4):451-475.
40. Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest. 2002;25:650-662.
41. Konrad D, Gartenmann M, Martin E, et al. Central diabetes insipidus as the first manifestation of neurosarcoidosis in a 10-year-old girl. Horm Res. 2000;54:98-100.
42. Stuart CA, Neelon FA, Lebovitz HE. Disordered control of thirst in hypothalamic- pituitary sarcoidosis. N Engl J Med. 1980;303:1078-1082.
43. Luciani JC, Conte-Devolx B, Fourcade JC, et al. Chronic hypernatremia, hypovolemia and partial hypopituitarism in sarcoidosis: a case report. Clin Nephrol. 1980;13:242-247.
44. Turkington RW, MacIndoe JH. Hyperprolactinemia in sarcoidosis. Ann Intern Med. 1972;76:545-549.
45. Tamagno G, Murialdo G. Amenorrhea-galactorrhea syndrome as an uncommon manifestation of isolated neurosarcoidosis. Ann Ital Med Int. 2001;16: 260-266.
46. Lalich RA, Aiman J. Pituitary sarcoidosis causing secondary amenorrhea. A case report. J Reprod Med. 1990;35:737-740.
47. Vesely DL, Maldonodo A, Levey GS. Partial hypopituitarism and possible hypothalamic involvement in sarcoidosis: report of a case and review of the literature. Am J Med. 1977;62:425-431.
48. Fery F, Plat L, van De Borne P, et al. Impaired counterregulation of glucose in a patient with hypothalamic sarcoidosis. N Engl J Med. 1999;340:852-856.
49. Guoth MS, Kim J, De Lotbiniere AC, et al. Neurosarcoidosis presenting as hypopituitarism and a cystic pituitary mass. Am J Med Sci. 1998;315:220-224.
50. Vesely DL. Hypothalamic sarcoidosis: a new cause of morbid obesity. South Med J. 1989;82:758-761.
51. Pillai P, Ray-Chaudhury A, Ammirati M, et al. Solitary pituitary sarcoidosis with normal endocrine function: case report. J Neurosurg. 2008;108:591-594.
52. Arle JE, Judkins AR, Kotapka MJ. Neurosarcoidosis presenting in the pituitary gland with normal endocrine studies. Skull Base Surg. 1999;9:149-153.
53. Jefferson M. Sarcoidosis of the nervous system. Brain. 1957;80:540-556.
54. Gjerse A, Kjerulif-Jensen K. Hypothalamic lesion caused by Boek's sarcoid. J Clin Endocrinol. 1950;10:1602-1608.
55. Vanhoof J, Wilms G, Bouillon R. [Hypothalamic hypopituitarism with hyperphagia and subacute dementia due to neurosarcoidosis: case report and literature review]. Acta Clin Belg. 1992;47:319-328.
56. Afshar K, Engelfried K, Sharma OP. Sarcoidosis: a rare cause of Kleine- Levine-Critchley syndrome. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25: 60-63.
57. Jaster JH, Dohan FC Jr, Bertorini TE, et al. Solitary spinal cord sarcoidosis without other manifestations of systemic sarcoidosis. Clin Imaging. 1997; 21:17-22.
58. Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:58-65.
59. Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16:289-296.
60. Hayashi T, Onodera J, Nagata T, et al.[A case of biopsy-proven sarcoid meningoencephalitis presented with hallucination, nominal aphasia and dementia]. Rinsho Shinkeigaku. 1995;35:1008-1011.
61. Bona JR, Fackler SM, Fendley MJ, et al. Neurosarcoidosis as a cause of refractory psychosis: a complicated case report. Am J Psychiatry. 1998;155: 1106-1108.
62. O'Brien GM, Baughman R, Broderick JP, et al. Paranoid psychosis due to neurosarcoidosis. Sarcoidosis. 1994;11:34-36.
63. Bourgeois JA, Maddock RJ, Rogers L, et al. Neurosarcoidosis and delirium. Psychosomatics. 2005;46:148-150.
64. Willigers H, Koehler PJ. Amnesic syndrome caused by neurosarcoidosis. Clin Neurol Neurosurg. 1993;95:131-135.
65. Friedman SH, Gould DJ. Neurosarcoidosis presenting as psychosis and dementia: a case report. Int J Psychiatry Med. 2002;32:401-403.
66. Sabaawi M, Gutierrez-Nunez J, Fragala MR. Neurosarcoidosis presenting as schizophreniform disorder. Int J Psychiatry Med. 1992;22:269-274.
67. Walbridge DG. Rapid-cycling disorder in association with cerebral sarcoidosis. Br J Psychiatry. 1990;157:611-613.
68. Stiller J, Goodman A, Komhi LM, et al. Neurosarcoidosis presenting as major depression. J Neurol Neurosurg Psychiatry. 1984;47:1050-1051.
69. McLoughlin D, McKeon P. Bipolar disorder and cerebral sarcoidosis. Br J Psychiatry. 1991;158:410-413.
70. Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997-1004.
71. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163:329-334.
72. Galassi G, Gibertoni M, Mancini A, et al. Sarcoidosis of the peripheral nerve: clinical, electrophysiological and histological study of two cases. Eur Neurol. 1984;23:459-465.
73. Koffman B, Junck L, Elias SB, et al. Polyradiculopathy in sarcoidosis. Muscle Nerve. 1999;22:608-613.
74. Miller R, Sheron N, Semple S. Sarcoidosis presenting with an acute Guillain-Barre syndrome. Postgrad Med J. 1989;65:765-767.
75. Nemni R, Galassi G, Cohen M, et al. Symmetric sarcoid polyneuropathy: analysis of a sural nerve biopsy. Neurology. 1981;31:1217-1223.
76. Verbraecken J, Hoitsma E, van Der Grinten CP, et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:137-146.
77. Jamal MM, Cilursu AM, Hoffman EL. Sarcoidosis presenting as acute myositis. Report and review of the literature. J Rheumatol. 1988;15:1868-1871.
78. Silverstein A, Siltzbach LE. Muscle involvement in sarcoidosis. Asymptomatic, myositis, and myopathy. Arch Neurol. 1969;21:235-241.
79. Christoforidis GA, Spickler EM, Recio MV, et al. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. Am J Neuroradiol. 1999;20:655-669.
80. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75-86.
81. Hayes WS, Sherman JL, Stern BJ, et al. MR and CT evaluation of intracranial sarcoidosis. Am J Roentgenol. 1987;149:1043-1049.
82. Miller DH, Kendall BE, Barter S, et al. Magnetic resonance imaging in central nervous system sarcoidosis. Neurology. 1988;38:378-383.
83. Sherman JL, Stern BJ. Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images. Am J Roentgenol. 1990;155:1293-1301.
84. Lury KM, Smith JK, Matheus MG, et al. Neurosarcoidosis-review of imaging findings. Semin Roentgenol. 2004;39:495-504.
85. Koyama T, Ueda H, Togashi K, et al. Radiologic manifestations of sarcoidosis in various organs. Radiographics. 2004;24:87-104.
86. Seltzer S, Mark AS, Atlas SW. CNS sarcoidosis: evaluation with contrastenhanced MR imaging. Am J Neuroradiol. 1991;12:1227-1233.
87. Kumpe DA, Rao CV, Garcia JH, et al. Intracranial neurosarcoidosis. J Comput Assist Tomogr. 1979;3:324-330.
88. Mirfakhraee M, Crofford MJ, Guinto FC Jr, et al. Virchow-Robin space: a path of spread in neurosarcoidosis. Radiology. 1986;158:715-720.
89. Sage MR. Blood-brain barrier: phenomenon of increasing importance to the imaging clinician. Am J Roentgenol. 1982;138:887-898.
90. Pickuth D, Spielmann RP, Heywang-Kobrunner SH. Role of radiology in the diagnosis of neurosarcoidosis. Eur Radiol. 2000;10:941-944.
91. Wilson JD, Castillo M, Van Tassel P. MRI features of intracranial sarcoidosis mimicking meningiomas. Clin Imaging. 1994;18:184-188.
92. Hollander MD, Friedman DP. Neuroradiology case of the day. Neurosarcoidosis. Radiographics. 1998;18:1608-1611.
93. Dumas JL, Valeyre D, Chapelon-Abric C, et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology. 2000;214:411-420.
94. Koike H, Misu K, Yasui K, et al. Differential response to corticosteroid therapy of MRI findings and clinical manifestations in spinal cord sarcoidosis. J Neurol. 2000;247:544-549.
95. Junger SS, Stern BJ, Levine SR, et al. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology. 1993; 43:333-337.
96. Aide N, Benayoun M, Kerrou K, et al. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol. 2007;80:e67-e71.
97. Dubey N, Miletich RS, Wasay M, et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci. 2002;205:77-81.
98. Mana J. Magnetic resonance imaging and nuclear imaging in sarcoidosis. Curr Opin Pulm Med. 2002;8:457-463.
99. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949-1953.
100. Oksanen V, Gronhagen-Riska C, Tikanoja S, et al. Cerebrospinal fluid lysozyme and beta 2-microglobulin in neurosarcoidosis. J Neurol Sci. 1986;73:79-87.
101. Li CY, Yam LT. Cytologic and immunocytochemical studies of cerebrospinal fluid in meningeal sarcoidosis. A case report. Acta Cytol. 1992;36:963-967.
102. Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol. 2006;253:488-495.
103. Tahmoush AJ, Amir MS, Connor WW, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:191-197.
104. Schweisfurth H, Schioberg-Schiegnitz S, et al. Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseases. Klin Wochenschr. 1987;65:955-958.
105. Oksanen V. New cerebrospinal fluid, neurophysiological and neuroradiological examinations in the diagnosis and follow-up of neurosarcoidosis. Sarcoidosis. 1987;4:105-110.
106. Khoury J, Wellik KE, Demaerschalk BM, et al. Cerebrospinal fluid angiotensin- converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist. 2009;15:108-111.
107. Dale JC, O'Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74:535.
108. Judson MA. The diagnosis of sarcoidosis. Clin Chest Med. 2008;29:415- 427, viii.
109. Patel AV, Stickler DE, Tyor WR. Neurosarcoidosis. Curr Treat Options Neurol. 2007;9:161-168.
110. Stern B. Neurosarcoidosis. Neurol Chron. 1992;2:1-6.
111. Vourlekis JS, Sawyer RT, Newman LS. Sarcoidosis: developments in etiology, immunology, and therapeutics. Adv Intern Med. 2000;45:209-257.
112. Constantino T, Digre K, Zimmerman P. Neuro-ophthalmic complications of sarcoidosis. Semin Neurol. 2000;20:123-137.
113. Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157:1864-1868.
114. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60-66.
115. Kouba DJ, Mimouni D, Rencic A, et al. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol. 2003;148:147-148.
116. O'Connor AS, Navab F, Germain MJ, et al. Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil. Dig Dis Sci. 2003;48:2191-2195.
117. Chaussenot A, Bourg V, Chanalet S, et al. Neurosarcoidosis treated with mycophenilate mofetil: two cases. Rev Neurol. 2007;163:471-475.
118. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124:2023-2026.
119. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55:1248-1254.
120. Carter JD, Valeriano J, Vasey FB, et al. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med. 15 2004;117:277-279.
121. Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroidrefractory neurosarcoidosis with infliximab. J Neurol. 2004;251:760-761.
122. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660-1661.
123. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064-1071.
124. Baughman R, Drent M, Kavaru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795-802.
125. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31:1189-1196.
126. Sodhi M, Pearson K, White ES, et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med. 2008;103:268-273.
127. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72:337-340.
128. Motta M, Alongi F, Bolognesi A, et al. Remission of refractory neurosarcoidosis treated with brain radiotherapy: a case report and a literature review. Neurologist. 2008;14:120-124.
129. Kang S, Suh JH. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig. 1999;7:309-312.
130. Menninger MD, Amdur RJ, Marcus RB Jr. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol. 2003;26:e115-e118.
131. Bejar JM, Kerby GR, Ziegler DK, et al. Treatment of central nervous system sarcoidosis with radiotherapy. Ann Neurol. 1985;18:258-260.
132. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001; 44:1496-1503.
133. Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol. 2004;17:311-316.